论文部分内容阅读
异基因造血干细胞移植是目前惟一能够治愈多发性骨髓瘤的方法,但清髓性异基因造血干细胞移植的高移植相关死亡率限制了其在临床的广泛应用。近年来,国外各研究组对如何减少移植相关并发症,提高长期生存进行了探索并取得了一定进展。
Allogeneic hematopoietic stem cell transplantation is the only method that can cure multiple myeloma. However, the high transplant-related mortality of myeloablative allogeneic hematopoietic stem cell transplantation limits its wide application in clinic. In recent years, all research groups abroad have made some exploration on how to reduce the complications related to transplantation and improve the long-term survival and have made some progress.